← Browse by Condition
Medical Condition

dlbcl

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for dlbcl sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — dlbcl Clinical Trials

How many clinical trials are currently recruiting for dlbcl?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for dlbcl, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for dlbcl?
dlbcl research spans Phase 1 (1 trial), Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a dlbcl clinical trial?
Eligibility criteria for dlbcl trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
3
Phase 3
1
Top Sponsors
Guangzhou Lupeng Pharmaceutical Company LTD. 1 trial
Merck Sharp & Dohme LLC 1 trial
Sun Yat-sen University 1 trial
University of Miami 1 trial

Recruiting Clinical Trials

NCT07570017 Phase 1
Recruiting
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Enrollment
42 pts
Location
China
Sponsor
Guangzhou Lupeng Pharmaceutica...
View Trial →
NCT05139017 Phase 2, Phase 3
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Enrollment
290 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT06569485 Phase 2
Recruiting
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
Enrollment
38 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06919939 Phase 2
Recruiting
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Enrollment
26 pts
Location
United States
Sponsor
University of Miami
View Trial →

Related Conditions

diffuse large b cell lymphoma (1) large b cell lymphoma (1) relapse (1) dlbcl diffuse large b cell lymphoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology